Associations between lifetime classic psychedelic use and cardiometabolic diseases.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 07 2021
13 07 2021
Historique:
received:
15
11
2020
accepted:
24
06
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
6
11
2021
Statut:
epublish
Résumé
The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005-2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65-0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78-0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.
Identifiants
pubmed: 34257396
doi: 10.1038/s41598-021-93787-4
pii: 10.1038/s41598-021-93787-4
pmc: PMC8277805
doi:
Substances chimiques
Hallucinogens
0
Psilocybin
2RV7212BP0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14427Informations de copyright
© 2021. The Author(s).
Références
J Psychopharmacol. 2019 Sep;33(9):1058-1067
pubmed: 30816808
J Psychoactive Drugs. 2020 Sep-Oct;52(4):289-299
pubmed: 32529966
JAMA Psychiatry. 2021 Feb 1;78(2):121-122
pubmed: 32725172
J Psychopharmacol. 2021 Apr;35(4):447-452
pubmed: 33719688
J Psychopharmacol. 2021 May 29;:2698811211008554
pubmed: 34053342
Lancet. 2017 Jun 3;389(10085):2239-2251
pubmed: 28190580
Lancet. 2010 Nov 6;376(9752):1558-65
pubmed: 21036393
Int Rev Psychiatry. 2018 Aug;30(4):363-375
pubmed: 30102081
Immunol Lett. 2020 Dec;228:45-54
pubmed: 33035575
J Psychopharmacol. 2018 Jan;32(1):37-48
pubmed: 29039233
J Am Coll Cardiol. 2019 Sep 10;74(10):e177-e232
pubmed: 30894318
N Engl J Med. 2021 Apr 15;384(15):1402-1411
pubmed: 33852780
JAMA Psychiatry. 2021 May 1;78(5):481-489
pubmed: 33146667
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Front Immunol. 2015 Jul 14;6:358
pubmed: 26236313
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
J Psychoactive Drugs. 2019 Apr-Jun;51(2):135-145
pubmed: 30732540
Front Pharmacol. 2016 Mar 02;7:35
pubmed: 26973523
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
Hypertension. 2021 May 5;77(5):1510-1516
pubmed: 33677982
Cardiovasc Psychiatry Neurol. 2009;2009:475108
pubmed: 20029624
Am J Med. 2016 Nov;129(11):1145-1148
pubmed: 27288855
Dialogues Clin Neurosci. 2018 Mar;20(1):47-52
pubmed: 29946211
Cell Metab. 2007 Nov;6(5):398-405
pubmed: 17983585
Circulation. 2010 Jul 27;122(4):406-41
pubmed: 20625115